The makers of Nuplazid (primavanserin), the new medicine for Parkinson's Disease Psychosis, have asked me to discuss ways to increase awareness of Parkinson’s disease psychosis (PDP) and identify what resources are needed within the community to provide more education and support. A focus group will meet next Wed., Dec. 7, to discuss this. Please let me know what you would like me to tell them.